It is with great excitement that RIC3D S.r.l. announces its participation in Slush 2022, which will be held on November 17 and 18 in Helsinki, at the Messukeskus.
As a matter of fact, RIC3D S.r.l. has been one of the Italian companies selected by ICE-ITA to strengthen the image of Made in Italy on the Finnish market by taking part in the acclaimed international trade fair, a key gathering point for the world’s leading professionals in the technological scenario.
Slush 2022, which was launched with the main purpose of founding the world’s largest startup community, reconfirms itself this year as Europe’s leading startup event. It will indeed see the participation of more than 4,600 startups, 2,600 investors and 400 journalists, offering participants an exceptional opportunity for networking and matchmaking between supply and demand.
The fair in its traditional set-up, with exhibitor spaces and resources to facilitate meetings between founders and investors, will be flanked by conferences and side events with the aim of enriching the agenda and facilitating new networking.
It is in this setting that the RIC3D team will have the opportunity to introduce their ROG project to important players of international caliber.
ROG is a highly interactive and responsive software application that allows users to perform virtual surgery simulation of the heart and other organs. Specifically, the software is able to digitize the organ in its true state and size through a patented method of generating 3D images of pathological tissues. The software, thus leveraging Virtual Reality and AI technologies, can locate the exact location of pathologies and allows users to interact with the organ and perform virtual surgical simulation activities. The project aims to strengthen the healthcare sector’s confidence in new technologies in order to accelerate their research, development and adoption to provide more and better care for patients in need.
Slush 2022 thus proves to be the ideal context for Techinnova to interact, compare and present, on a global level, its innovative projects in the medical field.